Jens Stahlschmidt

Jens Stahlschmidt

Auto-generated profile, based on publicly available information

Jens Stahlschmidt

Department of Histopathology and Molecular Pathology St James's University Hospital, Leeds Teaching Hospitals NHS Trust Leeds UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2025 in Histopathology
Verified
Journal Article
Closed access
JJJason A Jarzembowski
Jason A Jarzembowski
FWFleur Webster
Fleur Webster
KBKlaus Beiske
Klaus Beiske
SCSusan L Cohn
Susan L Cohn
Ronald de KrijgerRonald de Krijger
Ronald de Krijger
MRMiguel Reyes‐Mugica
Miguel Reyes‐Mugica

20 August 2025 in Histopathology
Verified
Journal Article
Open access
DLDolores H. Lòpez-Terrada
Dolores H. Lòpez-Terrada
FWFleur Webster
Fleur Webster
RARita Alaggio
Rita Alaggio
JBJonathan Bush
Jonathan Bush
SCSoo‐Jin Cho
Soo‐Jin Cho
MRMiguel Reyes‐Múgica
Miguel Reyes‐Múgica
Aims: Hepatoblastoma is the most common primary malignant tumour of the liver diagnosed in children and its incidence is increasing worldwide. Ongoing international clinical trials and scientific collaborative efforts are attempting to standardize the diagnosis, risk stratification and management of young patients diagnosed with this rare cancer, which includes surgical resection of the tumour. Here we report the international consensus‐based dataset for the pathology reporting of hepatoblastoma resection specimens. The dataset was developed under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of international pathology and cancer organizations. Methods and results: According to the ICCR's guidelines for dataset development, an international expert panel including paediatric pathologists and a paediatric oncologist specialized in liver tumours developed a set of core and non‐core data items for hepatoblastoma resection specimens based on critical review and discussion of current evidence available. Members of the panel were specialists working in tertiary paediatric hospitals, central reviewers for international paediatric liver tumours consortia and/or involved in paediatric liver tumour trials expert committees. Commentaries were provided to support each data item, explaining the rationale for selecting them as a ‘core’ or ‘non‐core’ elements, their clinical relevance and highlighting potential areas of lack of evidence, including clinical, macroscopic, microscopic and ancillary testing considerations. The hepatoblastoma dataset was finalized and ratified following international public consultation and is published on the ICCR website for wide implementation. Conclusion: This is the first international dataset developed by an international expert panel for reporting hepatoblastoma resection specimens aimed to promote high‐quality, standardized pathology reporting of these rare paediatric liver tumours. The adoption and implementation of this hepatoblastoma data set, freely available worldwide on the ICCR website ( www.iccr‐cancer.org/data‐sets ), will facilitate accurate reporting and enhance the consistency of data collection, support retrospective and inform prospective research and ultimately help to improve clinical outcomes of children with hepatoblastoma.

28 March 2022 in The American Journal of Pathology
Verified
Journal Article
Open access
JHJennifer Hinley
Jennifer Hinley
RDRosalind Duke
Rosalind Duke
JJJessica Jinks
Jessica Jinks
JSJens Stahlschmidt
Jens Stahlschmidt
DKDavid Keene
David Keene
JSJenny Southgate
Jenny Southgate
Bladder exstrophy (BEX) is a rare developmental abnormality resulting in an open, exposed bladder plate. Although normal bladder urothelium is a mitotically quiescent barrier epithelium, histologic studies of BEX epithelia report squamous and proliferative changes that can persist beyond surgical closure. The current study examined whether patient-derived BEX epithelial cells in vitro were capable of generating a barrier-forming epithelium under permissive conditions. Epithelial cells isolated from 11 BEX samples, classified histologically as transitional (n = 6) or squamous (n = 5), were propagated in vitro. In conditions conducive to differentiated tight barrier formation by normal human urothelial cell cultures, 8 of 11 BEX lines developed transepithelial electrical resistances of more than 1000 Ω.cm2, with 3 squamous lines failing to generate tight barriers. An inverse relationship was found between expression of squamous KRT14 transcript and barrier development. Transcriptional drivers of urothelial differentiation PPARG, GATA3, and FOXA1 showed reduced expression in squamous BEX cultures. These findings implicate developmental interruption of urothelial transcriptional programming in the spectrum of transitional to squamous epithelial phenotypes found in BEX. Assessment of BEX epithelial phenotype may inform management and treatment strategies, for which distinction between reversible versus intractably squamous epithelium could identify patients at risk of medical complications or those who are most appropriate for reconstructive tissue engineering strategies.

10 December 2021 in Der Pathologe
Verified
Journal Article
Closed access
PDF file
JSJens Stahlschmidt
Jens Stahlschmidt